Butyricimonas

Most gut bacteria on a stool report are there for volume. This one is there for a job. This bacterial group helps turn fermentable carbs that reach the colon into butyrate. Butyrate is a small fat-like acid that colon lining cells burn for energy and use to help keep the gut wall sealed.

That job is why the number is interesting, and also why it is easy to over-read. Research links both low and high abundance to disease, in different settings, and there are no standardized cutpoints. This is a research marker, useful as one line in a broader picture of gut function rather than an answer on its own.

What This Test Actually Measures

A stool microbiome assay reads bacterial DNA from your stool and reports how much of the total bacterial signal belongs to this genus. That word relative matters. If one group blooms, everything else can look lower without anyone actually disappearing. You are reading proportions, not headcounts.

The genus includes several named species, including Butyricimonas virosa, Butyricimonas synergistica, Butyricimonas paravirosa, and Butyricimonas faecihominis. A genus-level test does not tell you which one you carry. These species are strict anaerobes. They grow best where there is little to no oxygen, like the deeper colon.

The biology behind the name is the useful part. Butyrate is a main fuel for colonic lining cells. It also helps tighten the junctions between those cells and calm local inflammation. When fiber-fermenting bacteria thin out, that fuel supply and barrier support can weaken.

Inflammatory Bowel Disease

The best human signal for this genus comes from intestinal tissue, not from stool. In ulcerative colitis, biopsy samples from quiet colon lining had more of this genus and higher predicted butyrate-making activity than actively inflamed tissue from the same small study of 15 patients.

In children with Crohn's disease, tissue depletion helped predict who would relapse, with a discrimination score of 0.79 out of a possible 1.0. The study included 33 children with Crohn's disease, 23 with ulcerative colitis, and 26 controls. The stool samples in that study did not show this genus as a standalone predictor, so this is a tissue signal being used as context for a stool test.

Stool microbiome data point the same way in biologic-treated inflammatory bowel disease. Across two public cohorts plus a small local validation cohort, enrichment of this genus and related short-chain-fatty-acid producers was linked with remission. Nobody has shown that restoring the bacteria restores the drug response. What the data support is that the two travel together.

Butyrate Producers and Serious Infection

Step back from this one genus and the strongest human evidence in the field comes into view. Two population studies following 10,699 European adults found that people carrying more butyrate-producing bacteria overall were less likely to be hospitalized for an infection. Every 10 percent higher share of butyrate producers was linked to roughly 25 percent lower risk in the first cohort and 14 percent lower in the validation cohort.

Read that carefully. Those studies measured the whole guild of butyrate producers, not this genus specifically. It is evidence about the function this genus contributes to, not about your number for this genus. Useful context, not a direct claim about your result.

Cancer Findings That Point the Other Way

Here is where the simple story breaks. In people who had surgery for esophageal cancer after chemotherapy, higher stool abundance predicted recurrence and worse survival, with a discrimination score of 0.75 for survival. Higher, not lower, was the bad sign.

Elevated abundance has also turned up in esophageal squamous cell carcinoma, and single small studies have reported higher levels in colorectal adenomas and in cirrhosis with liver cancer. Those last two run against the broader literature, where butyrate producers are usually depleted across the adenoma-to-cancer sequence and in cirrhosis, so treat them as minority findings until someone repeats them. One small early-stage breast cancer study reported lower levels, which fits the more common pattern. Different cancers, opposite directions, all from small studies.

The way to hold both findings at once is to stop treating this as a good-number marker. Butyrate can slow cell growth through effects on how DNA is packaged, which looks protective in some settings. Mechanistic and animal work also suggest it can expand regulatory T cells. Regulatory T cells tell other immune cells to stand down. That can help in an inflamed colon, but near a tumor it could weaken immune surveillance. Whether your number is favorable depends on what is happening in your body, which is why this marker cannot be read in isolation.

Beyond the Gut

Depletion has been reported in several conditions outside the intestine. The pattern is consistent, but the studies are too small and too preliminary to act on.

• Multiple sclerosis: lower abundance was reported in untreated adults in an early study, with the genus tracking inversely with inflammatory gene expression and positively with anti-inflammatory genes. A later deconfounded analysis found that lowered butyrate producers, including this genus, deserve follow-up, but also showed how strongly stool moisture and other confounders can shape microbiome findings.
• Mild cognitive impairment: reduced levels were reported in older adults, correlating with attention and executive function in a case-control study of 96 people.
• Type 2 diabetes with H. pylori infection: lower abundance was reported alongside higher fasting glucose in a 44-person study.
• C. difficile: depletion was reported in toxigenic C. difficile-positive hospitalized patients compared with controls. In that study, the difference between symptomatic infection and asymptomatic carriage was not statistically clear for this genus.

These are mostly cross-sectional snapshots in small groups, and none has been independently replicated. They tell you the genus responds to illness. They do not tell you it causes any of it, and a Mendelian randomization analysis looking for causal microbial drivers of periodontitis found other taxa, not this one.

Bacteremia in Rare Cases

This genus belongs in your colon. Occasionally it escapes. One narrative review collected 14 published human infections, most in people who were immunocompromised or had serious underlying disease. The tally depends on which review you read: a 2024 case report and literature search counted 11 prior cases plus its own. The 16.7 percent mortality figure across cases with known outcomes comes from that single review and has not been checked against an independent count.

A dozen-odd cases in the world literature is the point. A stool result does not predict this, and a high number is not a warning sign of it. Bloodstream infection is diagnosed from blood cultures in someone who is acutely ill, not from a microbiome panel.

Why One Reading Tells You Almost Nothing

Variability changes how you should use this test. In healthy adults sampled daily, 78 percent of gut genera varied more within one person over six weeks than they differed between people, and 72 percent showed more than tenfold swings between consecutive samples. Another small study using repeated nearby samples found mean within-person variation of 57 percent across genera. Over a full year in a Swedish cohort, within-person change accounted for 23 percent of all variation in gut composition.

A single result is a weather report, not a climate reading. Stool water content, transit time, and what you ate in the preceding days can move the result enough that an unusual number on one sample may reflect a loose stool or a low-fiber weekend rather than a durable shift in your gut.

So treat your first result as a baseline and nothing more. Repeated samples are more useful than one, because they show how much your own number bounces. Over time you learn your personal range, which is the only reference range that exists for this marker.

When Your Result Can Mislead You

Four things distort a single reading more than the underlying biology does.

• Loose or watery stool: stool moisture is one of the strongest confounders in microbiome profiling, and studies that skip adjusting for it can generate false findings. Sample a normally formed stool.
• Recent antibiotics: these bacteria are strict anaerobes, and antibiotic courses reshape the anaerobic community for weeks to months. If you can, wait at least a month after finishing a course.
• Relative-abundance math: if another group blooms, this genus reads lower even when nothing happened to it. A drop is not proof of loss.
• Genus-level resolution: the assay cannot separate the species within the genus or tell you how much butyrate is being produced. Abundance is a proxy for a function, not the function.

What to Do With an Unexpected Result

Confirm before you interpret. Given the variability, a single odd number is not yet a finding. Check whether the pattern repeats on a second normally formed sample before drawing conclusions.

Then look at the company it keeps rather than the number alone. This genus is one line in a panel, and it only becomes meaningful next to the rest. Low levels alongside low total butyrate producers and low stool short-chain fatty acids point toward reduced fermentation capacity, which is a fiber and diversity question. Low levels alongside elevated calprotectin or lactoferrin point toward active intestinal inflammation, which deserves a gastroenterology workup rather than a diet adjustment. Low levels with a normal inflammatory picture and normal short-chain fatty acids mostly mean you caught a noisy sample.

Symptoms change the priority entirely. Persistent diarrhea, blood in the stool, unintentional weight loss, or fever means the right next test is a pathogen panel and stool inflammatory markers, not more microbiome profiling, and it means seeing a physician now. If you already have inflammatory bowel disease, changes here are worth showing your gastroenterologist as context alongside calprotectin and endoscopy, not as a substitute for either.

If you have had cancer treatment, resist reading this number as a recurrence signal. The esophageal cancer finding came from one surgical cohort, without adjustment for stage or treatment, and nobody has validated it for monitoring. Surveillance imaging and tumor markers remain the tools for that job.